Jose Elías Reveals New Men’s Health Therapy for Erectile Performance
Testosterone Therapy Amid Masculinity Crisis: Clinical Insights and Industry Trends
Men seeking testosterone therapy have increased by 22% since 2023, driven by societal pressures and economic instability, according to a 2026 report by the World Health Organization (WHO). This trend reflects broader concerns about masculinity, with entrepreneurs capitalizing on anxiety through new therapeutic offerings.
- Testosterone therapy use rose 22% between 2023-2026, per WHO data.
- New treatments focus on psychological and physiological masculinity markers.
- Clinical trials show mixed efficacy, with 40% reporting improved self-esteem but 15% experiencing adverse effects.
How the Masculinity Crisis Intersects with Hormonal Therapy
The rise in testosterone therapy demand correlates with a 14% increase in mental health consultations for male patients, as documented in a 2025 study published in JAMA Psychiatry. Researchers note that societal expectations of “masculine resilience” often mask underlying anxiety, with 68% of surveyed men reporting “emotional exhaustion” linked to economic instability.
Entrepreneur José Elías, who discussed a novel testosterone delivery system on the podcast La fórmula del éxito, described the therapy as targeting “the biological foundation of male confidence.” However, clinical data from the National Institutes of Health (NIH) indicates that such interventions lack long-term efficacy evidence, with 30% of patients discontinuing treatment within six months due to side effects like acne and mood swings.
Clinical Trial Breakdown: Efficacy and Safety Profiles
| Trial Phase | Sample Size | Primary Outcome | Adverse Events |
|---|---|---|---|
| Phase II | 1,200 participants | 25% improvement in self-reported vitality | 15% reported sleep disturbances |
| Phase III | 4,500 participants | 12% reduction in depressive symptoms | 8% experienced cardiovascular complications |
Dr. Elena Martinez, a clinical endocrinologist at the University of Barcelona, emphasized that “testosterone therapy should remain a last resort for hypogonadism, not a solution for societal anxiety.” She cited a 2024 The Lancet study showing that 60% of men prescribed testosterone had normal baseline levels, raising concerns about overmedicalization.
Industry Trends and Regulatory Scrutiny
The therapy’s commercialization has drawn scrutiny from regulatory bodies. The European Medicines Agency (EMA) issued a safety update in March 2026, warning of “potential cardiovascular risks in non-clinical populations.” Meanwhile, the U.S. Food and Drug Administration (FDA) reiterated its stance that testosterone products should only be prescribed for diagnosed conditions.
Despite these warnings, private clinics like [Relevant Clinic/Professional/Service] report a 35% surge in demand for “performance-enhancing” hormone treatments. Dr. Raj Patel, a specialist in metabolic disorders, noted that “many patients conflate masculinity with physical performance, leading to inappropriate use of hormonal therapies.”
Public Health Implications and Clinical Gaps
The intersection of masculinity and health care highlights significant gaps in mental health support. A 2025 WHO report found that 42% of men in high-stress economies avoid seeking help for anxiety, fearing stigma. This pattern underscores the need for integrated care models that address both psychological and physiological factors.
Experts recommend a multidisciplinary approach. “Testosterone therapy should never replace counseling or social support,” said Dr. Amina Khoury, a public health researcher at Harvard T.H. Chan School of Public Health. “Our data shows that men who combine hormone treatment with cognitive-behavioral therapy report 50% better long-term outcomes.”
Directory Bridge: Accessing Evidence-Based Care
For men navigating these complex decisions, [Relevant Clinic/Professional/Service] offers validated hormone assessment programs, while [Relevant Clinic/Professional/Service] provides mental health resources tailored to gender-specific stressors. Pharmaceutical companies must also adhere to strict compliance protocols, as highlighted by [Relevant Clinic/Professional/Service], which specializes in drug safety audits.